Monopar Therapeutics to Present at Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/13/2026

1. ORCL
2. ADBE
3. RH
4. SPY
5. CPRT

6. ACVA
7. SEDG
8. PMTS
9. KR
10. QQQ

Get Alerts MNPR Hot Sheet

Price: $110.26 +0.27%

Overall Analyst Rating:
SELL (= Flat)

EPS Growth %: -68.8%

Join SI Premium – FREE

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:

H.C. Wainwright Global Life Sciences ConferenceThe Company’s presentation will be webcast on Tuesday, March 9, 2021 at 7:00 a.m. ET

33rd Annual Roth Conference, Healthcare The Company’s fireside chat will be webcast on Tuesday, March 16, 2021 at 12:00 p.m. ET

Maxim’s 2021 Emerging Growth Virtual Conference Presentation time to be determined on Wednesday, March 17, 2021

About Monopar Therapeutics Inc.Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar’s pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc:Investor RelationsKim R. TsuchimotoChief Financial Officer[email protected]

Follow Monopar on social media for updates:

Twitter: @MonoparTx LinkedIn: Monopar Therapeutics